West German Study Group

2 in Phase 3

Quick facts

Phase 3 pipeline

Myocet · Other
Standard-of-care endocrine treatment · Oncology
Blocks estrogen receptors to prevent cancer cell growth.

Phase 2 pipeline

Trastuzumab Biosimilar ABP 980

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: